Blog

TNF Family

The tumor necrosis factor superfamily (TNFSF) is a group of proteins that play a wide and important role in biology. Currently, 19 ligands have been identified in this family, such as TNF-α, TNF-β, CD40L, FasL, TRAIL, RANKL, etc., and 29 receptors correspond to them. TNFSF members are all type II transmembrane proteins, and their C - terminal contains a TNF - homologous domain, which can promote the formation of trimeric complexes of ligands and receptors, thus activating the intracellular signaling pathway. These ligands regulate a variety of cellular functions by binding to different receptors, including immune response, inflammatory response, cell proliferation, differentiation, apoptosis and embryogenesis, etc., playing a key role in maintaining body homeostasis and responding to external stimuli. For example, TNF - α is abnormally expressed in a variety of tumors, which can promote tumor growth, angiogenesis, invasion and metastasis, and at the same time inhibit apoptosis, while TRAIL can selectively induce tumor cell apoptosis and become a new target for tumor treatment. In addition, the over - expression of CD40L is related to a variety of autoimmune diseases, such as lupus erythematosus and rheumatoid arthritis, and the abnormal RANKL/RANK signal is related to osteoporosis.

Product List

Validation Data

GMP Recombinant Human TNF-α (Catalog: PCH90043)

                      TNF-α SDS-PAGE image

           Bioactivity image: The ED50 for this effect is 5-60 pg/mL.

GMP Recombinant Human EGF (Catalog: PCH90003)

                         EGF SDS-PAGE image

           Bioactivity image: The ED50 for this effect is ≤0.3 ng/mL.

GMP Recombinant Human EPO (Catalog: PCH90004)

                         EPO SDS-PAGE image

           Bioactivity image: The ED50 for this effect is ≤0.01 ng/mL.

GMP Recombinant Human Fibronectin (Catalog: PCH90013)

                    Fibronectin SDS-PAGE image

Bioactivity image: The ED₅₀ for this effect is ＜0.5 ng/ml, corresponding to a specific activity of ≥ 1×10⁷ units/mg.

GMP Recombinant Human Fibronectin (Catalog: PHH90051)

                     Fibronectin SDS-PAGE image

           Bioactivity image: The ED50 for this effect is ≤0.2 ng/mL.

GMP Recombinant Human Fibronectin (Catalog: PEH90052)         GMP Recombinant Human Fetuin A (Catalog: PCH90005)

                   Fibronectin SDS-PAGE image

          Bioactivity image: The ED50 for this effect is 50-200 μg/mL.

GMP Recombinant Human FLT-3L (Catalog: PCH90014)

                       FLT-3L SDS-PAGE image

Bioactivity image: The ED50 as determined by the dose-dependent stimulation of the proliferation of human OCI-AML5 cells is ≤ 1.0 ng/ml, corresponding to a specific activity of ≥ 1×10⁶ units/mg.

GMP Recombinant Human LIF (Catalog: PCH90033)                          GMP Recombinant Human HGF (Catalog: PCH90017)  

                         LIF SDS-PAGE image

             Bioactivity image: The ED₅₀ for this effect is≤20 ng/mL.

GMP Recombinant Mouse LIF (Catalog: PCM90056)

                  Mouse LIF SDS-PAGE image

                                  Mouse LIF Bioactivity image

GMP Recombinant Human Noggin (Catalog: PCH90035)

                     Noggin SDS-PAGE image

          Bioactivity image: The ED50 for this effect is 2.0-3.0 ng/ml.

GMP Recombinant Human PDGF-BB (Catalog: PPH90037)

                      PDGF-BB SDS-PAGE image

           Bioactivity image: The ED50 for this effect is ≤10 ng/mL.

GMP Recombinant Human R-Spondin1 (Catalog: PCH90038)

                     R-Spondin1 SDS-PAGE image

         Bioactivity image: The ED50 for this effect is 1.0-3.0 μg/ml.

GMP Recombinant Human SCF (Catalog: PCH90039)

                        SCF SDS-PAGE image

             Bioactivity image: The ED50 for this effect is 5-8 ng/mL.

References

1. Signalling pathways of the TNF superfamily: a double-edged sword. Aggarwal BB. Nat Rev Immunol. 2003. [PMID: 12949498]

2. The TNF-TNF receptor system. Hehlgans T, et al. Biol Chem. 2002. PMID: [12452434]

3. TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Rivas MA, et al. Exp Cell Res. 2008. [PMID: 18061162]